Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML
Jundan Xie, Xiebing Bao, Shengli Xue, Hongjie Shen, Jiannong Cen, Yao Li, Jinlan Pan, Mingqing Zhu, Dandan Liu, Xiaohui Hu, Qian Wu, Jing‐Ren Zhang, Haiping Dai, Yanglin Cao, Xuefeng He, Xiaowen Tang, Aining Sun, Ying Wang, Jianhong Fu, Huiying Qiu, Xiaofei Yang, Suning Chen, Depei Wu
Abstract
Xie et al present results of a multicenter, single-arm phase 2 trial of venetoclax and decitabine as frontline treatment in 42 younger adults (median age 39 years) with newly diagnosed adverse risk acute myeloblastic leukemia (AML). Remission was achieved in 39 of 42 patients (93%), 36 of whom went on to allogeneic stem cell transplant. Efficacy is encouraging, with estimated 12-month overall survival, event-free survival, and duration of response being 82%, 61%, and 65% respectively.